Laurus Labs Q1 FY27: Revenue up 29%, EBITDA margin expands to 31.8%
LAURUSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Q1 FY27 revenue rose 29% YoY to INR 2,026 crores, driven by CDMO growth of 69% to INR 835 crores. EBITDA margin expanded 7 percentage points to 31.8%, with PAT at INR 368 crores and ROCE at around 19%. Affordable Medicines grew 10% to INR 1,156 crores. Capex guidance raised to INR 2,000 crores from INR 1,500 crores for FY27 to meet customer demand. Management targets CDMO at 50%+ of revenue by FY30, asset turnover above 1.0x, and long-term ROCE of 25%.
Strong quarter with margin expansion and raised capex guidance signals management confidence. Targets CDMO at 50%+ revenue by FY30, supported by a diversified pipeline.